UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000055069
Receipt number R000062911
Scientific Title Predicting the treatment effect of heavy ion particle therapy for cervical cancer: Mathematical modeling and machine learning
Date of disclosure of the study information 2024/07/25
Last modified on 2024/07/25 01:56:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Predicting the treatment effect of heavy ion particle therapy for cervical cancer: Mathematical modeling and machine learning

Acronym

Predicting the treatment effect of heavy ion particle therapy for cervical cancer: Mathematical modeling and machine learning

Scientific Title

Predicting the treatment effect of heavy ion particle therapy for cervical cancer: Mathematical modeling and machine learning

Scientific Title:Acronym

Predicting the treatment effect of heavy ion particle therapy for cervical cancer: Mathematical modeling and machine learning

Region

Japan


Condition

Condition

cervical cancer

Classification by specialty

Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Aiming to establish a method for predicting the therapeutic effects of heavy-ion therapy for cervical cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Check the extent to which the results of the treatment effect prediction model created and the actual treatment effect match the following items for consideration.
Items for consideration: local control rate, recurrence-free survival rate, distant metastasis incidence rate, overall survival rate, etc.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

The study subjects are patients who underwent heavy ion therapy for cervical cancer at QST Hospital between June 1995 and May 2023.

Key exclusion criteria

Patient data for which the subject of the research has requested that it not be used shall be excluded.

Target sample size

250


Research contact person

Name of lead principal investigator

1st name Kazutoshi
Middle name
Last name Murata

Organization

National Institutes for Quantum Science and Technology QST hospital

Division name

Department of Diagnostic Radiology and Radiation Oncology

Zip code

2638555

Address

4-9-1 Anagawa, Inage-ku, Chiba City

TEL

0432063306

Email

murata.kazutoshi@qst.go.jp


Public contact

Name of contact person

1st name Kazutoshi
Middle name
Last name Murata

Organization

National Institutes for Quantum Science and Technology QST hospital

Division name

Department of Diagnostic Radiology and Radiation Oncology

Zip code

2638555

Address

4-9-1 Anagawa, Inage-ku, Chiba City

TEL

0432063306

Homepage URL


Email

murata.kazutoshi@qst.go.jp


Sponsor or person

Institute

National Institutes for Quantum Science and Technology

Institute

Department

Personal name

Kazutoshi Murata


Funding Source

Organization

National Institutes for Quantum Science and Technology

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Institutes for Quantum Science and Technology Certified Review Board

Address

4-9-1 Anagawa, Inage-ku, Chiba City

Tel

0432063306

Email

murata.kazutoshi@qst.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 07 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 09 Month 06 Day

Date of IRB


Anticipated trial start date

2023 Year 09 Month 06 Day

Last follow-up date

2023 Year 09 Month 06 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is an observational study.
Cases that meet the conditions of this study and for which the research subject or other party does not request refusal by November 30, 2023, will be registered as cases for this study. Data collection and analysis will be conducted on or after December 1, 2023.
The following clinical data will be collected from the Heavy Ion Therapy Medical Database (TMS), the clinical database (AMIDAS), and medical records.
Clinical data necessary for predicting treatment efficacy
Data indicating treatment efficacy
Using past treatment results from heavy ion therapy for cervical cancer, we will establish a mathematical model to predict the effects of heavy ion therapy based on multiple clinical data such as patient background and treatment details.
In addition, a machine learning model for predicting treatment efficacy will be constructed using supervised learning, with clinical data as the input. In order to efficiently learn from clinical data that is partially missing for each case, missing information will be supplemented and data pre-processed. Furthermore, by analyzing the computational behavior of the trained model and the importance of the input data, the types and order of the clinical data required for predicting treatment efficacy for each case will be calculated. From these results, we aim to establish a prognosis prediction model using machine learning and develop a more intuitive and effective mathematical model for predicting treatment efficacy.


Management information

Registered date

2024 Year 07 Month 25 Day

Last modified on

2024 Year 07 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000062911


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name